Halozyme Therapeutics: Huge Deals & Forecast Upgrades Ignite the Stock
Reading Time: 3 minutes
Massive forecast upgrade: A huge profit leap and new top annual targets after strong quarterly results drive institutional buying interest. Megatrend beneficiary: The proprietary ENHANZE platform makes drug delivery highly efficient and continuously attracts new pharmaceutical giants. Buying pressure from professionals: Renowned analysts like Leerink Partners are calling ambitious record price targets. A massive earnings leap under record volume brings Halozyme Therapeutics significantly into the focus of institutional buyers after...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
